Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843460 | 0.98 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2FGFR1 | |
| Lithium Ion SCHEMBL1843469 | 0.91 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2 | |
| Lithium SCHEMBL1843829 | 0.88 | ABL1 (0.37) | ABL1 | |
| Lithium SCHEMBL1841528 | 0.88 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2FGFR1 | |
| SCHEMBL1843807 | 0.86 | ABL1 (0.37) | ABL1 | |
| SCHEMBL1841516 | 0.86 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2FGFR1 | |
| SCHEMBL1841508 | 0.86 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2FGFR1 | |
| Lithium SCHEMBL1842854 | 0.86 | ABL1 (0.43) | ABL1NPC1RAB9ASMN1; SMN2 | |
| Lithium SCHEMBL1843044 | 0.86 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2FGFR1 | |
| SCHEMBL1841659 | 0.86 | NPC1 (0.43) | ABL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | claimed |
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | disclosed |
| EP-2321309-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009156966-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | TOP2B, TOP1, POLI | ABL1 1206/4885NPC1 3448/4885RAB9A 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.